- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Niagen Bioscience Inc (NAGE)
The Niagen Bioscience share price today is 3.280, view NASDAQ NAGE stock exchange data. Track the latest Niagen Bioscience share price with real-time updates on NAGE stock performance including market cap, day range, 52-week range and dividend yield. Access NAGE charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.260
3.410
52 wk Range
3.175
11.290
NAGE is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.2603.410
52 wk Range
3.17511.290
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NAGE Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
12.000
Upside
+265.85%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 12.000
(+265.85% Upside)
Niagen Bioscience Inc Earnings Call Summary for Q3/2025
- Niagen Bioscience (NAGE) exceeded Q3 2025 forecasts with EPS of $0.05 vs $0.02 expected and revenue of $34M vs $30.83M expected, despite stock dipping 3.73% after hours.
- Revenue grew 33% year-over-year to $34M with net income rising to $4.6M from $1.9M in Q3 2024, driven by a 109% increase in distribution business.
- Gross margin improved to 64.5% (up 100 basis points), with the company maintaining a strong cash position of $64.3M and no debt.
- Management revised full-year revenue growth guidance to 25-30%, announcing plans to launch a telehealth platform for at-home injections by mid-2026.
- Key challenges include regulatory hurdles like the FDA's NMN ruling, intense competition in NAD precursor products, and potential economic pressures on consumer spending.
Last Updated: 05-11-2025, 04:04 am
Read Full TranscriptEarnings
Latest Release
06-05-2026
EPS / Forecast
0.07 / 0.08
Revenue / Forecast
31.5M / 30.23M
Compare NAGE to Peers and Sector
Metrics to compare | NAGE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNAGEPeersSector | |
|---|---|---|---|---|
P/E Ratio | 14.0x | −2.6x | 11.5x | |
PEG Ratio | 0.81 | 0.01 | 0.03 | |
Price/Book | 3.2x | 3.0x | 1.5x | |
Price / LTM Sales | 2.0x | 2.1x | 0.9x | |
Upside (Analyst Target) | 250.6% | 5.8% | 24.5% | |
Fair Value Upside | Unlock | 16.2% | 14.0% | Unlock |
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Niagen Bioscience (NAGE) Share Price Today?
The Niagen Bioscience share price today is 3.280.
What is the current Niagen Bioscience (NAGE) share price and day range?
As of 19-07-2026, the Niagen Bioscience share price is 3.280, with a previous close of 3.400. The share price has ranged from 3.260 to 3.410 today, while the 52-week range spans from 3.175 to 11.290.
What Is the Niagen Bioscience Market Cap?
As of today, Niagen Bioscience market cap is 261.780M.
What Is the Niagen Bioscience (NAGE) Share Price Target?
The average 12-month share price target for Niagen Bioscience is 12.000, with a high estimate of 18 and a low estimate of 9. 6 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +265.85% Upside potential.
What Is Niagen Bioscience's Earnings Per Share (TTM)?
The Niagen Bioscience EPS (TTM) is 0.210.
When Is the Next Niagen Bioscience Earnings Date?
Niagen Bioscience will release its next earnings report on 12-08-2026.
From a Technical Analysis Perspective, Is NAGE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Niagen Bioscience Trade On?
Niagen Bioscience is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Niagen Bioscience?
The stock symbol for Niagen Bioscience is "NAGE."
How Many Times Has Niagen Bioscience Stock Split?
Niagen Bioscience has split 1 times.
How Many Employees Does Niagen Bioscience Have?
Niagen Bioscience has 117 employees.
What Is the NAGE Premarket Price?
NAGE's last pre-market stock price is 3.390. The pre-market share volume is 6,760.000, and the stock has changed by -0.010, or -0.290%.
What Is the NAGE After Hours Price?
NAGE's last after hours stock price is 3.320, the stock has changed by 0.040, or 1.220%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.